Accordingly, a phase 1 dose escalation and expansion study with an anti-CD38 Ab, CID-103, is currently recruiting previously treated, relapsed or refractory multiple myeloma patients (ClinicalTrials.gov Identifier: NCT04758767). This evidence concerns the gene CD38 and AL amyloidosis.